Randomized controlled trial · strong evidence
Tesamorelin for reduction of visceral adipose tissue in HIV-associated lipodystrophy
Citation
Falutz J, et al. Tesamorelin for reduction of visceral adipose tissue in HIV-associated lipodystrophy. New England Journal of Medicine. 2010.
- Study type
- Randomized controlled trial
- Population / sample
- ~800 adults with HIV-associated abdominal fat accumulation
- Intervention
- Daily subcutaneous tesamorelin vs placebo
- Journal
- New England Journal of Medicine (2010)
- Authors
- Falutz J, et al.
Key finding
In this randomized, placebo-controlled trial, participants receiving tesamorelin had a measurable reduction in visceral adipose tissue compared with placebo over the study period. The trial was conducted in a specific HIV population, and results may not generalize to other groups.